Sarepta Therapeutics, Inc. 8K

Sarepta Therapeutics’ CEO Douglas S. Ingram is retiring and transitioning to a paid consulting role through year-end 2026 with continued equity vesting and reaffirmed restrictive covenants.

Sarepta Therapeutics, Inc. entered into a Consulting and Advisory Agreement with its retiring Chief Executive Officer, Douglas S. Ingram, effective July 28, 2026, under which he will serve as an independent contractor advisor to the new CEO through December 31, 2026 for a $15,000 monthly consulting fee, remain a service provider for purposes of continued vesting and exercisability of his existing equity awards (subject to specified retirement and vesting provisions), and reaffirm his existing restrictive covenants and confidentiality obligations, while formally resigning from all officer and board positions as of the effective date.

Filing Facts

CIK

873303

Ticker

SRPT

Form

8K

Source Type

fda

Accession

0001193125-26-316995

Alert Tier

8